Johnson G, Valdés RYC, Polo VJC, Marcel EA

Language: Spanish
References: 13
Page: 127-132
PDF size: 256.56 Kb.

ABSTRACT

The breast cancer is one of the most frequent and heterogeneous diseases in women. In clinical, the tumor markers are employees in the prognosis and evaluation of the response to therapy. Tumor markers (CEA, CA 15-3) are useful in the follow-up and evaluation of response to treatment. Objective: To determine the association between the levels of the tumors’ markers of CEA and CA 15-3 in a sample of patients classified in different groups according to the breast cancer. Results: The general half age was of 49.7 although there was women’s prevalence with 46-50 years (69%). The carcinoma ductal infiltrates (IDC) it showed in incidence of 30% in the studied sample, besides 24% of family history of cancer. Also, they were significant association relationships between the distribution of the levels of CEA and CA 15-3 regarding family history and type of diagnosed tumor and of CA-15-3 regarding the age, particularly in the group 46 years they registered the highest levels. Conclusion: The incidence of the IDC was of waiting then it is one of the types more common of cancer of he/she suckles. On the other hand, the significant differences of the levels of CEA and CA 15-3 respect to family load and tumor type is an evidence of the clinical value of the combination of both markers in the characterization of the studied patients; while, the significant variations of CA 15-3 regarding age suggest a bigger diagnostic sensibility.

REFERENCES

1. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006; 24: 2137-2150.

2. Willett WC, Rockhill B, Hankinson SE, Hunte D, Colditz GA. Epidemiology and Nongenetic Causes of Breast Cancer. In: Harris J et al. Diseases of the breast. Ad: Second Edition 2000; IV: 175-220.

3. Hernández D, Borges R, Márquez G, Betancourt L. Factores de riesgo conocidos para cáncer de mama. Rev Venez Oncol. 2010; 22 (1): 16-31.

4. Campuzano MG. Utilidad clínica de los marcadores tumorales. Medicina & Laboratorio. 2010; 16 (9-10): 411-445.

5. Molina R, Jo J, Filella X, Zanon G, Farrus B, Muñoz M et al. C-erbB-2, CEA and CA 15.3 serum levels in the early diagnosis of recurrence of breast cancer patients. Anticancer Res. 1999; 19: 2551-2555.

6. Ali SM, Leitzel K, Chinchilli VM, Engle L, Demers L, Harvey HA et al. Relationship of serum HER-2/neu and serum CA 15-3 in patients with metastatic breast cancer. Clin Chem. 2002; 48: 1314-1320.

7. Molina R, Augé JM, Escudero JM, Filella X, Zanon G, Pahisa J et al. Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with loco regional breast cancer: prognostic value. Tumour Biol. 2010; 31: 171-180.

8. Leonard GD, JA Low, AW Berman, SM Swain. CA 125 elevation in breast cancer: a case report and review of the literature. Breast J. 2004; 10: 146-149.

9. Baskić D, Ristić P, Matić S, Banković D, Popović S, Arsenijević N. Clinical evaluation of the simultaneous determination of CA 15-3, CA 125 and sHER2 in breast cancer. Biomarkers. 2007; 12: 657-667.

10. Uehara M, Kinoshita T, Hojo T et al. Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer. Int J Clin Oncol. 2008; 13 (5): 447-451.

11. López N, Ramón N, Sánchez JI, De Santiago J. Metástasis óseas múltiples de cáncer de mama. Papel del CA 15.3 y respuesta a la hormonoterapia. Rev Chil Obstet Ginecol. 2012; 77 (4): 291-295.

12. Malkin D, Li FP, Strong LC et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasm’s. Science. 1990; 30 (250): 1233-1238.

13. Claus EB, Rish N, Thompson WD. Genetic analysis of breast cancer in the cancer and steroid hormone study. Am J Hum Genet. 1991; 48: 232-242.